21
Participants
Start Date
January 16, 2020
Primary Completion Date
July 4, 2022
Study Completion Date
July 4, 2022
APVO101
Subjects will receive a single IV dose of APVO101 twice weekly or at a frequency of infusions as determined appropriate by the investigator for the particular study subject for a total of 50 ED. The starting prophylaxis dose will be based on APVO101 recovery from PK Phase assessments (only pre-infusion and 15-30 minute post-infusion samples).
Worthwhile Clinical Trials, Lakeview Hospital, Benoni
Haemophilia Comprehensive Care Centre, Johannesburg
Ege University School ofMedicine, Izmir
State Institute: Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine, Lviv
Centro Estadual de Hemopterapia e Hematologia do Espirito Santo, Vitória
Universidade Estadual de Campinas - Centro de Hematologia e Hemoterapia, Campinas
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Ribeirão Preto
JSC K Eristavi National Center for Experimental and Clinical Surgery, Tbilisi
PMSI Institute of Mother and Child, Chisinau
Cukurova University School of Medicine, Adana
National Specialized Children's Hospital OKHMATDYT, Kyiv
Lead Sponsor
Medexus Pharma, Inc.
INDUSTRY